Multidisciplinary approaches are crucial in treating complex cancer patients, focusing on tailored therapies and symptom management strategies.
Saad Z. Usmani, MD, MBA, FACP, FASCO
Advertisement
Articles by Saad Z. Usmani, MD, MBA, FACP, FASCO
Saad Usmani, MD, MBA, FACP, FASCO, explores treatment duration, patient characteristics, and toxicity profiles in transplant-ineligible patients with newly diagnosed multiple myeloma.
Saad Usmani, MD, MBA, FACP, FASCO, discusses the subgroup analysis of transplant-ineligible patients with newly diagnosed multiple myeloma from the CEPHEUS trial.
Advertisement
Latest Updated Articles
ASCO 2025: Fixed-Duration Treatment Emerges as Future of Multiple Myeloma ManagementPublished: June 4th 2025 | Updated:
ASCO 2025: Quadruplet Therapy Shows Promise in Transplant-Ineligible Multiple MyelomaPublished: June 2nd 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
How a New Generation of CAR T-Cell Therapies Could Reduce the Risk of Rejection
2
FDA, ASH Experts Review Newly Approved Therapies in Hemophilia
3
A Cup of Coffee or Life-Saving Drugs: Shifting Decision-Making Practices in Health Care
4
Specialty Pharmacy's Expanding Role in IBD Care and Biosimilar Education
5
